Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses.
A simple blood test for a brain protein tracks disease severity in rare fatal brain disorders, enabling shorter and more feasible clinical trials.
Neurofilament light chain (NfL) demonstrated strong utility as a surrogate biomarker of neurological disease severity and progression in GM2 gangliosidoses (Tay-Sachs and Sandhoff disease) across multiple centers. Validated NfL levels as a trial endpoint enables shorter, more feasible clinical trials for these fatal ultra-rare diseases.
What the study was
- Study design
- multicenter_observational_cohort
- Category
- rare_diseases
- Maturity
- Potentially Practice-Changing
Why it surfaced
GM2 gangliosidoses (Tay-Sachs/Sandhoff) are fatal rare diseases with no approved therapy. Multicenter NfL biomarker validation directly enables future clinical trials with feasible endpoints. Directly relevant to rare diseases watchlist; multicenter design gives strong evidentiary weight.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.